A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer

Mollon, Lea; Anderson, Elizabeth J.; Dean, Joni; Warholak, Terri; Aizer, Ayal A.; Platt, Emma; Tang, Derek; Davis, Lisa E.

doi:10.1016/j.clbc.2019.08.011

Cited by 35 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PI3K inhibitors show different activities in a range of different populations, indicating that there is a need for patient selection. PIK3CA mutation may serve as a potential predictive marker, which is of considerable interest in trials so far ( Mollon et al, 2020 ). Notably, the combination of fulvestrant and alpelisib has shown synergistic antitumor activity against ER+/PIK3CA-mutated advanced BC ( André et al, 2019 ).…”

Section: Potential Predictive Biomarkers Of Response or Resistance Tomentioning

confidence: 99%

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.

show abstract

Section: Potential Predictive Biomarkers Of Response or Resistance Tomentioning

confidence: 99%

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…PIK3CA mutation is one of the most common mutations in human cancer. It has been identified as a biomarker of breast cancer ( Haefliger et al, 2020 ; Mollon et al, 2020 ), cervical cancer, endometrial cancer, ovarian cancer and parathyroid adenoma cancer ( Milano, 2020 ; Riccardi et al, 2020 ). Mutations in exon 9 and 20 of PIK3CA are closely related to colorectal cancer ( Jin et al, 2020 ).…”

Section: Common Point Mutations and Related Diseasesmentioning

confidence: 99%

Biosensors for Point Mutation Detection

Jiang

Juhas

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

“…PIK3CA had lower mutation frequencies in the high-risk patients than in the low-risk patients. PIK3CA mutations may be associated with worse clinical outcomes (Mollon et al, 2019). In comparison, 63 genes with significant mutation frequencies were identified by comparing all stage III-IV samples with all stage I-II samples using Fisher's exact test (p < 0.05) and the mutation frequencies are low.…”

Section: Genomic Characteristics Of the Prognostic Groupsmentioning

confidence: 99%

A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer

Cai

Song

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

About 20-30% of early-stage breast cancer patients suffer relapses after surgery. To identify such high-risk patients, many signatures have been reported, but they lack robustness in data measured on different platforms. Here, we developed a signature which is robust across multiple profiling platforms, and identified reproducible omics features characterizing metastasis of estrogen receptor (ER)-positive breast cancer from the Gene Expression Omnibus database with the aid of the signature. Based on the stable within-sample relative expression orderings (REOs), we constructed a signature consisting of five gene pairs, named 5-GPS, whose REOs were significantly correlated with relapse-free survival using the univariate Cox regression model. Using 5-GPS, patients were classified into the low-risk and high-risk groups. Patients in the high-risk group have worse survival compared to those in the low-risk group using Kaplan-Meier curve analysis with the log-rank test. Applying 5-GPS to the RNA-sequencing data of stage I-IV breast cancer samples archived in The Cancer Genome Atlas (TCGA), we found that the proportion of the high-risk patients increases with the stage. The proposed REO-based signature shows potential in identifying early-stage ER+ breast cancer patients with high risk of relapse after surgery.

show abstract

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer

Cited by 35 publications

References 44 publications

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Biosensors for Point Mutation Detection

A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer

Contact Info

Product

Resources

About